LNG-IUS

PreclinicalSmall molecule

Bayer

LNG-IUS is one of 11 small molecule programs targeting Adenomyosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

AdenomyosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Adenomyosis

#DrugCompanyPhaseTrials

Bayer Aspirin

Femara

Zoladex

TTerSera Therapeutics LLC

Ofev

1 5

Prometrium

Ferring

Phase 3

1 6

Dienogest

Bayer

Phase 3

4 7

Trelstar

OOncoVerity, Inc.

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

1 9

Drospirenone

EExeltis France

Preclinical

1 10

Gnrh Agonist and Letrozole

IIndira IVF Hospital Pvt Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients

Completed·KKing Chulalongkorn Memorial Hospital·Phase 4·NCT02534688·50 enrolled

Adenomyosis1 trial

Adenomyosis: Genomic Mechanisms and Biological Response

Withdrawn·UUniversity of Texas Southwestern Medical Center··NCT03428854

Hysterectomy1 trial

Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia

Completed·UUniversity of Helsinki·Phase 3·NCT00966264·236 enrolled

Hormone Replacement Therapy1 trial

Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Completed· Bayer logo

Bayer·Phase 3·NCT00185458·394 enrolled

Unspecified1 trial

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

Completed· Bayer logo

Bayer·Phase 3·NCT01397097·766 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LNG-IUS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LNG-IUS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LNG-IUS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

LNG-IUS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

Adenomyosis1 trial

Hysterectomy1 trial

Hormone Replacement Therapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News